Internetiühendust pole — kuvatakse lehe salvestatud versioon.

Novartis AG ADR

USUSD
← Aktsiafiltri juurde
US:NVSEFLSE:0QLRMI:1NOVNSW:NOVNSW:NOVNEEVI:NOVNXETRA:NOT

Novartis AG ADR (XETRA:NOT) — Drug Manufacturers - General. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 7. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.

Ettevõtte kohta

Veebileht
novartis.com
Sektor
Healthcare · Drug Manufacturers - General
Peakontor
BASEL, Switzerland
Tegevjuht
Dr. Vasant Narasimhan M.D.
Töötajad
75 267
Asutatud
1996
Ringluses olevad aktsiad
1.91 mld seisuga 2025-12-31
Vabalt kaubeldavad aktsiad
1.86 mld
Turukapitalisatsioon
276.48 mld USD
Siseringi isikud
0.01%
Institutsionaalsed investorid
7.27%
Tegevusala (SIC)
Pharmaceutical Preparations
Õiguslik vorm
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Väljamaksesuhe
56.0%
FCF
17.6 mld USD
44%
Võlg
29.4 mld USD
1.0 a FCF
Dividendistaaž
20 a
Kasum, FCF ja dividendid makstud — 12 kuu jooksul kuni 31.12.2025 (ettevõtte viimane raport).
Kirjeldus

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Börsid ja tikkerid

BörsTikkerValuutaHindTüüp
US USA StocksNVSEF OTCUSD135.75 +1.14%tavalised aktsiad
LSE London Stock Exchange0QLR IOBCHF82.63 +0.00%tavalised aktsiad
MI Borsa Italiana (Milan)1NOVN lisanoteeringEUR127.94 +1.33%tavalised aktsiad
SW SIX Swiss ExchangeNOVN põhinoteeringCHF119.8 -0.13%tavalised aktsiad
SW SIX Swiss ExchangeNOVNEE lisanoteeringCHF120.02 -1.80%tavalised aktsiad
VI Vienna Stock ExchangeNOVN lisanoteeringEUR127.32 -0.31%tavalised aktsiad
XETRA XetraNOT lisanoteeringEUR126.82 +0.48%tavalised aktsiad

Hind 3 kuu jooksul

3M1Y3Y5Y
tõususepäev langusepäev dividendi ex-kuupäev väljamakse kuupäevViige kursor / puudutage päeva — avamis-, sulgemis-, kõrgeim ja madalaim hind

Dividendid

Viimased 12 kuud, XETRA:NOT: 3.9091 EUR (1 väljam.)

Novartis AG ADR (NOT) maksab dividende kord aastas. Viimase 12 kuu jooksul maksti 3.9091 EUR aktsia kohta (maksed: 1). See on umbes 3.08% praegusest aktsiahinnast. Makseajaloo põhjal oodatakse järgmist ex-dividendi kuupäeva umbes 09.03.2027. Katkematu dividendiajalugu: 20 aastat.

Ex-kuupäevVäljamakseSumma%TüüpTikker
2026-03-10—3.9091 EUR3.1/3.1 %aastaneXETRA:NOT
2025-03-11—3.6978 EUR2.9/2.9 %aastaneXETRA:NOT

Selle nädala uudised

Ettevõtte veebisaidilt uudiseid veel pole.

reklaam

Suurimad omanikud

OmanikOsalusAktsiadAruande kuupäev
VANGUARD STAR FUNDS-Vang…1.35%27.43 mln2026-07-31
VANGUARD TAX-MANAGED FUN…0.9%18.24 mln2026-06-30
Fisher Asset Management,…0.76%15.52 mln2026-06-30
iShares Trust-iShares Co…0.67%13.69 mln2026-08-31
Goldman Sachs TRT II-Gol…0.6%12.19 mln2026-07-31
Artisan Partners Funds I…0.51%10.29 mln2026-06-30
Dodge & Cox Funds-Dodge…0.44%8.9 mln2026-06-30
Morgan Stanley0.43%8.73 mln2026-06-30
Dimensional Fund Advisor…0.4%8.12 mln2026-06-30
Fidelity Concord Street…0.35%7.12 mln2026-07-31
Primecap Management Comp…0.32%6.59 mln2026-06-30
iShares Trust-iShares MS…0.32%6.53 mln2026-08-31
LOOMIS SAYLES & CO L P0.26%5.24 mln2026-06-30
MFS Series Trust XVII-MF…0.26%5.22 mln2026-06-30
Bank of America Corporat…0.24%4.91 mln2026-06-30
VANGUARD SPECIALIZED FUN…0.23%4.66 mln2026-07-31
VANGUARD CHESTER FUNDS-V…0.21%4.25 mln2026-06-30
Franklin Resources, Inc.0.16%3.25 mln2026-06-30
Blackrock Inc.0.15%3.05 mln2026-06-30
Goldman Sachs Group Inc0.15%2.98 mln2026-06-30
Northern Trust Corporati…0.14%2.79 mln2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 mln2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 mln2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 mln2026-06-30
Franklin Mutual Series F…0.06%1.19 mln2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30
Pacer Advisors, Inc.0.02%482 1532026-06-30
Partners Capital Investm…0%24 3352026-06-30
Paradigm Asset Managemen…0%21 5142026-06-30
Generali Investments Cee…0%15 7292026-06-30